Search

What do systematic reviews say?

6 questions · 7 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Casirivimab/imdevimab vs placebo

Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

2 findings from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs usual care

Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs usual care

Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found